Regional Cerebral Metabolism and Treatment in Autism Spectrum Disorders
By Sherie Novotny, M.D., and Eric Hollander, M.D.
May 1, 2003
Dr. Novotny is clinical assistant professor at the Mount Sinai School of Medicine and the Seaver Autism Research Center.
Dr. Hollander is professor of psychiatry at the Mount Sinai School of Medicine and clinical director of the Seaver Autism Research Center and the Center for Impulsive, Compulsive and Anxiety Disorders.
The work discussed in this paper is supported in part by grants from the Seaver Foundation, Orphan Products Division of the U.S. Food and Drug Administration grants #FD-R-001520-03 and #FD-R-002026, National Institute of Neurological and Developmental Disorders grant #1 R21 NS43979-01, and National Alliance for Research in Schizophrenia and Depression.
Buchsbaum MS, Hollander E, Haznedar MM et al. (2001), Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 4(2):119-125.
Buitelaar JK, Willemsen-Swinkels SH (2000), Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatr Drugs 2(1):67-81.
Buxbaum JD, Silverman JM, Smith CJ et al. (2002), Association between a GABRB3 polymorphism and autism. Mol Psychiatry 7(3):311-316.
Chakrabarti S, Fombonne E (2001), Pervasive developmental disorders in preschool children. JAMA 285(24):3093-3099 [see comment].
Chugani DC, Muzik O, Rothermel R et al. (1997), Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 42(4):666-669.
Chugani DC, Sundram BS, Behen M et al. (1999), Evidence of altered energy metabolism in autistic children. Prog Neuropsychopharmacol Biol Psychiatry 23(4):635-641.
Ciaranello RD, VandenBerg SR, Anders TF (1982), Intrinsic and extrinsic determinants of neuronal development: relation to infantile autism. J Autism Dev Disord 12(2):115-145.
Friedman SD, Shaw DW, Artru AA et al. (2003), Regional brain chemical alterations in young children with autism spectrum disorder. Neurology 60(1):100-107.
Handen BL, Johnson CR, Lubetsky M (2000), Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30(3):245-255.
Hardan AY, Handen BL (2002), A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 12(3):237-241.
Haznedar MM, Buchsbaum MS, Metzger M et al. (1997), Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Am J Psychiatry 154(8):1047-1050 [see comment].
Haznedar MM, Buchsbaum MS, Wei TC et al. (2000), Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging. Am J Psychiatry 157(12):1994-2001.
Hollander E, Cartwright C, Wong CM et al. (1998), A dimensional approach to the autism spectrum. CNS Spectrums 3(3):22-39.
Hollander E, Dolgoff-Kaspar R, Cartwright C et al. (2001), An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 62(7):530-534.
Hollander E, Novotny S, Allen A et al. (2000), The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22(2):163-167.
Kahne D, Tudorica A, Borella A et al. (2002), Behavioral and magnetic resonance spectroscopic studies in the rat hyperserotonemic model of autism. Physiol Behav 75(3):403-410.
Lee M, Martin-Ruiz C, Graham A et al. (2002), Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125(pt 7):1483-1495.
McBride PA, Anderson GM, Hertzig ME et al. (1989), Serotonergic responsivity in male young adults with autistic disorder. [Published erratum Arch Gen Psychiatry 46(5):400.] Arch Gen Psychiatry 46(3):213-221.
McCracken JT, McGough J, Shah B et al. (2002), Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314-321 [see comments].
McDougle CJ, Naylor ST, Cohen DJ et al. (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53(11):1001-1008 [see comments].
McDougle CJ, Naylor ST, Goodman WK et al. (1993), Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 33(7):547-550.
Novotny S, Hollander E, Allan A et al. (2000), Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Res 94(2):173-177.
Otsuka H, Harada M, Mori K et al. (1999), Brain metabolites in the hippocampus-amygdalaregion and cerebellum in autism: an 1H-MR spectroscopy study. Neuroradiology 41(7):517-519.
Posey DJ, McDougle CJ (2000), The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 8(2):45-63.
Purcell AE, Jeon OH, Zimmerman AW et al. (2001), Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 57(9):1618-1628.
Robinson PD, Schutz CK, Macciardi F et al. (2001), Genetically determined low maternal serum dopamine beta-hydroxylase levels and the etiology of autism spectrum disorders. Am J Med Genet 100(1):30-36.
Strauss WL, Unis AS, Cowan C et al. (2002), Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 159(5):755-760.
Tordjman S, Gutknecht L, Carlier M et al. (2001), Role of the serotonin transporter gene in the behavioral expression of autism. Mol Psychiatry 6(4):434-439.